Related Experiment Videos
Predictive markers in breast cancer--the future
1Endocrine Cancer Group, Edinburgh Cancer Research Centre, Edinburgh, UK.
Histopathology
|January 4, 2008
Summary
Despite numerous promising breast cancer biomarkers, few reach clinical use. This review explores challenges and highlights potential candidates like topoisomerase II alpha and epidermal growth factor receptor for future therapy prediction.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Many tissue biomarkers show promise for predicting breast cancer therapy response.
- A significant gap exists between laboratory discovery and clinical application of these biomarkers.
Purpose of the Study:
- To discuss reasons for the limited clinical translation of breast cancer biomarkers.
- To highlight candidate biomarkers in development for near-future clinical use.
- To explore the role of molecular biology in hypothesis-driven biomarker discovery.
Main Methods:
- Literature review of published research on breast cancer biomarkers.
- Discussion of selected biomarkers including topoisomerase II alpha, epidermal growth factor receptor, AKT, and phosphatase and tensin homologue.
- Analysis of statistical considerations for biomarker validation.
Main Results:
- Identified challenges hindering clinical progression of biomarkers.
- Presented potential biomarkers (e.g., topoisomerase II alpha, EGFR) for future clinical application.
- Emphasized the importance of understanding molecular pathways for biomarker development.
Conclusions:
- Bridging the gap between biomarker discovery and clinical utility requires addressing specific challenges.
- Continued research in molecular and pathway biology, coupled with robust statistical validation, is crucial for successful biomarker implementation in breast cancer treatment.